Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Mersana Therapeutics, Inc. Banner

Mersana Therapeutics, Inc.

MRSN Stock Analysis

Page title

Section title

Breakdown
2015
2016
2017
2018
2019
2020
2021
2022
2023
Net Income
-16.428m-13.700m-38.707m-64.257m-28.208m-88.045m-170.060m-204.212m-171.670m
Depreciation & Amortization
297.000K655.000K928.000K1.257M1.245M1.010M855.000K927.000K1.517M
Change in Working Capital
6.146M43.965M-6.029m4.176M-45.534m5.105M10.085M133.099M-18.763m
Operating Cash Flow
-9.636m31.588M-42.679m-55.216m-67.744m-74.696m-139.988m-49.363m-168.882m
Capital Expenditure
-619.000k-1.084m-1.143m-1.370m-605.000k-473.000k-648.000k-2.197m-2.168m
Free Cash Flow
-10.255m30.504M-43.822m-56.586m-68.349m-75.169m-140.636m-51.560m-171.050m
Debt Repayment
0.0000.0000.0000.000-87.000k-313.000k-5.701m-272.000k-93.127m
Dividends Paid
0.0000.0000.0000.0000.0000.0000.0000.0000.000
Common Stock Issued
9.960M58.259M68.145M1.064M92.162M227.026M43.087M2.396M1.548M
Common Stock Repurchased
0.0000.0000.000146.000K489.000K561.000K640.000K1.065M1.121M
Net Change in Cash
-459.000k88.763M-73.706m33.043M2.667M192.743M-76.990m-49.062m45.676M